StockData
Skye Bioscience, Inc. logo

Skye Bioscience, Inc. (SKYE) stock

SKYENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 3/30
$1.00−0.06 (-6.10%)

Close on Nov 17, 2026Market cap $35.42MP/E –Yield –

Skye Bioscience operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Skye Bioscience's operating cash flow for the twelve months ending Jun 30, 2026 was -$38.81M. For fiscal 2025 it was -$43.06M. The highest annual figure on record is $1.93K in fiscal 2012.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$43.06M–
FY2024Dec 31, 2024-$25.24M–
FY2023Dec 31, 2023-$13.95M–
FY2022Dec 31, 2022-$12.74M–
FY2021Dec 31, 2021-$6.47M–
FY2020Dec 31, 2020-$6.05M–
FY2019Dec 31, 2019-$6.03M–
FY2018Dec 31, 2018-$3.94M–
FY2017Dec 31, 2017-$3.33M–
FY2016Dec 31, 2016-$3.55M–
FY2015Dec 31, 2015-$3.73M–
FY2013Oct 31, 2013-$14.50K-851.8%
FY2012Oct 31, 2012$1.93K–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$7.12M–
Q1 FY2026Mar 31, 2026-$8.56M–
Q4 FY2025Dec 31, 2025-$9.77M–
Q3 FY2025Sep 30, 2025-$13.36M–
Q2 FY2025Jun 30, 2025-$10.75M–
Q1 FY2025Mar 31, 2025-$9.19M–
Q4 FY2024Dec 31, 2024-$8.17M–
Q3 FY2024Sep 30, 2024-$5.26M–
Q2 FY2024Jun 30, 2024-$7.09M–
Q1 FY2024Mar 31, 2024-$4.71M–
Q4 FY2023Dec 31, 2023-$3.84M–
Q3 FY2023Sep 30, 2023-$4.05M–
Q2 FY2023Jun 30, 2023-$1.99M–
Q1 FY2023Mar 31, 2023-$4.06M–
Q4 FY2022Dec 31, 2022-$4.87M–
Q3 FY2022Sep 30, 2022-$2.06M–
Q2 FY2022Jun 30, 2022-$2.90M–
Q1 FY2022Mar 31, 2022-$2.91M–
Q4 FY2021Dec 31, 2021-$1.97M–
Q3 FY2021Sep 30, 2021-$1.49M–
Q2 FY2021Jun 30, 2021-$1.67M–
Q1 FY2021Mar 31, 2021-$1.35M–
Q4 FY2020Dec 31, 2020-$1.79M–
Q3 FY2020Sep 30, 2020-$1.97M–
Q2 FY2020Jun 30, 2020-$1.03M–
Q1 FY2020Mar 31, 2020-$1.27M–
Q4 FY2019Dec 31, 2019-$1.50M–
Q3 FY2019Sep 30, 2019-$1.49M–
Q2 FY2019Jun 30, 2019-$1.61M–
Q1 FY2019Mar 31, 2019-$1.43M–
Q4 FY2018Dec 31, 2018-$1.01M–
Q3 FY2018Sep 30, 2018-$816.28K–
Q2 FY2018Jun 30, 2018-$1.06M–
Q1 FY2018Mar 31, 2018-$1.05M–
Q4 FY2017Dec 31, 2017-$2.14M–
Q3 FY2017Sep 30, 2017-$99.95K–
Q2 FY2017Jun 30, 2017-$271.41K–
Q1 FY2017Mar 31, 2017-$816.41K–
Q4 FY2016Dec 31, 2016-$662.78K–
Q3 FY2016Sep 30, 2016-$511.73K–

More Skye Bioscience figures

See a number that looks wrong?